期刊文献+

Preparation of lomustine loaded liposomes and studies of its pharmacokinetics and tissue distribution properties

洛莫司汀脂质体的制备及药代动力学和组织分布学研究(英文)
原文传递
导出
摘要 Liposomes are used as carriers for targeted drug delivery by the intravenous route. The aim of our study was to prepare lomustine loaded liposomes (CCNU-Lips) and evaluate its physicochemical properties and the tissue targeting after intravenous (i.v.) injection. CCNU-Lips were prepared by film dispersion method. In vitro drug release was investigated in phosphate-buffered saline (pH 6.8) at 37℃. The concentrations of CCNU in selected organs were determined using reversed-phase high-performance liquid chromatography (HPLC) following i.v. administration of CCNU-Lips and inclusion complex solution of CCNU with hydroxypropyl-β-cyclodextrin (CCNU-Sol). CCNU-Lips had an average diameter of (189.8±28.5) nm with a zeta potential of (-19.13±0.12) mV and the in vitro drug release was monitored for up to 3 d, and the release behavior was in accordance with Weibull-equation. The CCNU-Lips exhibited a longer elimination half life (t1/2β) in vivo compared with CCNU-Sol after i.v. injection to New Zealand rabbits. The encapsulation of lomustine in liposomes also changed its biodistribution in mice. CCNU-Lips showed significant brain targeting with AUC, Te and Re of the brain all showing obvious elevation. These results indicated that CCNU-Lips were promising passive targeting formulation to the brain. 脂质体是可静脉注射的靶向、控释给药系统。本研究的主要目的是制备洛莫司汀脂质体,评价其物理化学性质,并对其静脉注射后的组织靶向性进行研究。用薄膜分散法制备洛莫司汀脂质体,37℃磷酸盐缓冲溶液(pH=6.8)中考察体外释放特性,反相高效液相色谱法测定静脉注射洛莫司汀HP-β-CD包合物溶液和脂质体后组织中的药物浓度。该实验制备的洛莫司汀脂质体平均粒径为(189.8±28.5)nm,zeta电位(-19.13±0.12)mV。释放曲线符合Weibull方程。以新西兰兔为试验动物,分别静脉注射洛莫司汀溶液和脂质体,脂质体组的消除半衰期(t_(1/2β)显著增加。洛莫司汀脂质体在小鼠脑组织中的AUC、Te和Re明显提高。实验结果表明该脂质体对脑部有被动靶向效果。
机构地区 山东大学药学院
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS 2010年第5期353-362,共10页 中国药学(英文版)
关键词 Liposomes Lomustine (CCNU) Passive targeting PHARMACOKINETICS Sustained release system Tissue distribution 脂质体 洛莫司汀 被动靶向 药代动力学 缓释系统 组织分布
  • 相关文献

参考文献37

  • 1Mane, J.M.; Barcelo, J.R.; Rubio, I.; Femandez, R.; Fuente, N.; Abon, G.; Mufioz, A.; Lopez-Vivanco, G. Eur. J. Cancer. 1999, 35, S120.
  • 2Li, J.H.; Kang, S.J.; Ma, S.D.; Xie, J.M. Lung Cancer. 1999, 25, S17.
  • 3Claudette, R.B.; Russell, J.G.; Alexander, M.S.; Rodney, J.Y.H. CancerRes. 2001, 61, 3669-3674.
  • 4Lewandowicz, G.M.; Harding, B.; Harkness, W. Eur. J. Cancer 2000, 36, 1955-1964.
  • 5Xu, G.C.; Rong, T.H.; Lin, P. Chin. Med. J (Engl Ed). 2000, 113, 617~520.
  • 6Shen, Y.Y.; Qiu, L.Y.; Jin, Y. Chin. J. Pharm. Anal. 2005, 25, 317-319.
  • 7Pardridge, W. Mol. lnter. 2003, 3, 90-105.
  • 8Samad, A.S.; Aqil, M. Curr. DrugDel. 2007, 4, 297-305.
  • 9Soni, V.; Kohi, D.V.; Jain, S.K.J. Drug Target. 2005, 13, 245-250.
  • 10Das, D.; Lin, S. J. Pharm. Sci. 2005, 94, 1343-1353.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部